Pharmaxis Faces New Study Requirement For CF Drug Bronchitol
This article was originally published in Pharmaceutical Approvals Monthly
In a “complete response” letter, FDA says efficacy has not been adequately demonstrated for use of dry powder mannitol in cystic fibrosis patients ages six years and older.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Pulmonary-Allergy Drugs Advisory Committee votes 9-7 that the benefits of Pharmaxis' cystic fibrosis drug outweigh its risks, leaving the FDA with a muddled verdict.
Bronchitol is set to make its second appearance before a US FDA advisory committee, and Chiesi hopes to rely on the drug’s novel mechanism of action and the unmet need in cystic fibrosis to overcome the agency’s concerns about the underlying clinical data.